請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/63516
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 楊偉勛(Wei-Shiung Yang) | |
dc.contributor.author | Yi-Hsin Lin | en |
dc.contributor.author | 林毅欣 | zh_TW |
dc.date.accessioned | 2021-06-16T17:13:29Z | - |
dc.date.available | 2021-02-23 | |
dc.date.copyright | 2021-02-23 | |
dc.date.issued | 2021 | |
dc.date.submitted | 2021-02-03 | |
dc.identifier.citation | [1] Davies MJ, D'Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41:2669-701. [2] Turner LW, Nartey D, Stafford RS, Singh S, Alexander GC. Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012. Diabetes Care 2014;37:985-92. [3] McIntosh CH, Demuth HU, Pospisilik JA, Pederson R. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? Regul Pept 2005;128:159-65. [4] Mikhail N. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential. Vasc Health Risk Manag 2008;4:1221-7. [5] Wu D, Li L, Liu C. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Obes Metab 2014;16:30-7. [6] Wang F, He Y, Zhang R, Zeng Q, Zhao X. Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients. Medicine (Baltimore) 2017;96:e7638. [7] White WB, Heller SR, Cannon CP, Howitt H, Khunti K, Bergenstal RM; EXAMINE Investigators. Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial. Am J Med 2018;131:813-19. [8] Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab. 2011; 13:7–18. [9] Kirby M, Yu DM, O'Connor S, Gorrell MD. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin Sci (Lond) 2009;118:31-41. [10] Han R, Wang X, Bachovchin W, Zukowska Z, Osborn JW. Inhibition of dipeptidyl peptidase 8/9 impairs preadipocyte differentiation. Sci Rep 2015;5:12348. [11] Wu S, Hopper I, Skiba M, Krum H. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: Meta-analysis of randomized clinical trials with 55,141 participants. Cardiovasc Ther 2014;32:147–58. [12] Kim WJ, Park CY, Jeong EH, et al. Retrospective analysis on the efficacy, safety and treatment failure group of sitagliptin for mean 10-month duration. Diabetes Metab J 2011;35:290-7. [13] Lim S, An JH, Shin H, et al. Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study. Clin Endocrinol (Oxf) 2012;77(2):215-23. [14] Nomiyama T, Akehi Y, Takenoshita H, et al. Contributing factors related to efficacy of the dipep¬tidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2012;95:e27-8. [15] Esposito K, Chiodini P, Maiorino MI, et al. A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24163 patients. BMJ Open 2015;5:e005892. [16] Yagi S, Aihara K, Akaike M, et al. Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus. Diabetes Metab J 2015;39:342-47. [17] Chen YW, Wang JS, Sheu WH, et al. Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes. PLoS One 2017;12:e0171753. [18] Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145: 247–54. [19] Lin YH, Huang H. Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus. Diabetes Metab Syndr Obes 2019;12:2725-33. [20] Maeda H, Kubota A, Tanaka Y, Terauchi Y, Matsuba I; ASSET-K Study group. The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 dia¬betes. Diabetes Res Clin Pract 2012;95:e20-2. [21] Esposito K, Chiodini P, Capuano A, Maiorino MI, Bellastella G, Giugliano D. Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitors: meta-regression analysis of 78 randomized controlled trials with 20,053 patients. Endocrine 2014;46:43–51. [22] Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: A meta-regression analysis. Diabetes Care 2006;29:2137–9. [23] Esposito K, Chiodini P, Bellastella G, Maiorino MI, Giugliano D. Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: Systematic review of 218 randomized controlled trials with 78945 patients. Diabetes Obes Metab 2012;14:228–33. [24] Matthews DR, Paldánius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S; VERIFY study group. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet 2019;394:1519-29. [25] Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-49. [26] American Diabetes Association. Standards of medical care in diabetes: 2018. https://professional.diabetes.org/slidelibrary/standards-medical-care-diabetes-2018 [27] Shaw JE, Bloomgarden ZT. Individualizing therapy: do we have the tools to do it? J Diabetes 2015;7:1–2. [28] Bihan H, Ng WL, Magliano DJ, Shaw JE. Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review. Diabetes Res Clin Pract 2016;121:27-34. [29] Kirino Y, Sei M, Kawazoe K, Minakuchi K, Sato Y. Plasma di¬peptidyl peptidase 4 activity correlates with body mass index and the plasma adiponectin concentration in healthy young people. Endocr J 2012;59:949-53. [30] Færch K, Torekov SS, Vistisen D, et al. GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study. Diabetes 2015;64:2513-25. [31] Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996;379:69-72. [32] Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132:2131-57. [33] Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995;80: 952-7. [34] Mortensen K, Christensen LL, Holst JJ, Orskov C. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept 2003;114:189-96. [35] Cai X, Han X, Luo Y, Ji L. Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on β-cell function in Asian and Caucasian type 2 diabetes mellitus patients: A meta-analysis. J Diabetes 2015;7:347-59. [36] Graefe-Mody U, Retlich S, Friedrich C. Clinical pharmacokinetics and pharmacodynamics of linagliptin. Clin Pharmacokinet 2012;51:411–27. [37] Hu P, Yin Q, Deckert F, et al. Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers. J Clin Pharmacol 2009;49:39–49. [38] Brath H, Paldánius PM, Bader G, Mathieu C. Relationship Between Duration of Type 2 Diabetes and Effectiveness of DPP-4 Inhibitor Versus Sulfonylurea as Add-on Therapy: A Post Hoc Analysis. Diabetes Ther 2017;8:829-36. [39] Moritoh Y, Takeuchi K, Hazama M. Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice. Diabetes Obes Metab 2010;12:224-33. [40] Kishimoto M, Noda M. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers. Cardiovasc Diabetol 2011;10:115. [41] Hirao K, Maeda H, Shirabe S, et al. Combination therapy with a dipeptidyl peptidase-4 inhibitor, sulfonylurea, and metformin markedly improves HbA1c levels in Japanese patients with type 2 diabetes mellitus. Jpn Clin Med 2012;3:1-7. [42] Del Prato S, Felton AM, Munro N, Nesto R, Zimmet P, Zinman B; Global Partnership for Effective Diabetes Management. Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. Int J Clin Pract 2005;59:1345-55. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/63516 | - |
dc.description.abstract | 背景與目的:Dipeptidyl Peptidase-4 (DPP-4) inhibitors是十五年來最受歡迎的口服降血糖藥物。它主要是靠抑制DPP-4這個胜肽酶,去提升內生性腸泌素,進而使胰島素增加分泌及減少昇糖素的分泌,達成降低血糖的效果。使用此藥物其低血糖的風險較低、降糖化血紅素的效果中等(下降ΔHbA1c: 0.5-0.9%)、對體重不太會有改變、方便使用(大多是一天一顆)、及很少有嚴重的副作用。在台灣目前還不清楚何種類的患者使用DPP-4 Inhibitors會受益。本研究的目的想要分析台灣第二型糖尿病患初次使用DPP-4 Inhibitors之效益預測因子。
方法:本研究為回溯觀察性研究,收錄193位(122為男性)第二型糖尿病患初次使用DPP-4 Inhibitors,其平均年齡58.0 ± 12.6歲,患病時間5.4 ± 4.7年,身體質量指數26.1 ± 4.3 kg/m2,預測腎絲球過濾率95.9 ± 27.0 mL/min/1.73M2,觀察其使用後六個月的HbA1c的變化。 結果:這193位使用者大都是將DPP-4 Inhibitors放在第二或第三線的治療 (平均使用2.8 ± 0.7種口服降糖藥)、其平均基準HbA1c: 8.4 ± 1.4%,經過六個月的使用後,平均下降HbA1c 1.1 ± 1.2% (P <0.01)。統計分析下,基準HbA1c較高的組群有較顯著的HbA1c下降效果(ΔHbA1c ≥0.5%)。簡單線性回歸分析發現六個月治療後HbA1c的改變與患者的基準HbA1c呈正相關(R = 0.71, P <0.001)。多元線性回歸分析發現較高基準HbA1c level、較低身體質量指數、較短糖尿病患病時間、使用較少種類的口服降糖藥是降低HbA1c的貢獻因子。 結論:本研究發現較高基準HbA1c level、較低身體質量指數、較短糖尿病患病時間、較少使用口服降糖藥是台灣第二型糖尿病患使用DPP-4 Inhibitors效益預測因子,尤其是基準HbA1c level在有效療效(ΔHbA1c ≥0.5%)中起著最重要的作用。 | zh_TW |
dc.description.abstract | Background/purpose: Dipeptidyl peptidase-4 (DPP-4) inhibitors are the most popular oral antidiabetic drugs (OADs) in recent 15 years because of lower risk of hypoglycemia, intermediate efficacy to lower glycated hemoglobin (ΔHbA1c): 0.5-0.9%, neutral effect on body weight change, convenience for usage (mostly once daily), and rare occurrence of major side effects. It had not been established which patients would benefit from the treatment of DPP-4 inhibitors in Taiwan. The purpose of this study was to investigate the predictors of the efficacy of naïve use of DPP-4 inhibitors in Taiwanese patients with type 2 diabetes mellitus (T2D).
Methods: A retrospective observational study was conducted. Of the T2D patients, 193 (122 men) naïve DPP-4 inhibitor users with an age of 58.0 ± 12.6 years, disease duration of 5.4 ± 4.7 years, body mass index (BMI) of 26.1 ± 4.3 kg/m2, and estimated glomerular filtration rate of 95.9 ± 27.0 mL/min/1.73M2 were assessed for change of HbA1c in 6 months. Results: After 6 months of DPP-4 inhibitors use, mostly as second- or third-line of oral antidiabetic drugs (2.8 ± 0.7 kinds of OADs), 193 T2D patients (mean baseline HbA1c: 8.4 ± 1.4%) had reduction of HbA1c 1.1 ± 1.2% on average (P <0.01). The group with a higher baseline HbA1c level had better efficacy (defined asΔHbA1c ≥0.5%) in lowering HbA1c. Single regression analysis showed that the change in HbA1c after 6 months of treatment was positively associated with the baseline HbA1c level (R = 0.71, P <0.001). In addition, multiple regression analysis showed that the contributors to reduction of HbA1c level after 6 months were higher baseline HbA1c level, lower BMI, shorter T2D duration, and use of fewer kinds of OADs. Conclusion: Our study suggested that higher baseline HbA1c level, lower BMI, shorter T2D duration, and use of fewer kinds of OADs were the predictors of the efficacy of DPP-4 inhibitors in Taiwanese patients with T2D. The baseline HbA1c level, in particular, played the most important role in predicting efficacy (ΔHbA1c ≥0.5% at 6 months). | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T17:13:29Z (GMT). No. of bitstreams: 1 U0001-0302202100042100.pdf: 3102925 bytes, checksum: 74c31e0f5a62dc3b533b5d13df18b175 (MD5) Previous issue date: 2021 | en |
dc.description.tableofcontents | 口試委員會審定書……………………………………………………………………..# 誌謝……………………………………………………………………………………..i 中文摘要……………………………………………………………………………….ii ABSTRACT……………………………………………………………………………iii CONTENTS…………………………………………………………………………….v LIST OF FIGURES…………………………………………………………………....vii LIST OF TABLES…………………………………………………………………….viii Chapter 1 Background and Literature review...……….……...………………….1 1.1 Background…………………………………………………………......1 1.2 Literature review……………………………………………………….3 Chapter 2 Research Design and Methods………………………………………...6 2.1 Research design and study subjects…………………………………...6 2.2 Exclusion criteria……………………………………………………….6 2.3 Research disclosure……………………………………………………..7 2.4 Statistical analysis……………………………………………………....7 Chapter 3 Results…………………………………………………………………...9 3.1 Patient disposition and characteristics…………..…………………...9 3.2 The effective (ΔHbA1c ≥0.5%) group had a significantly higher baseline HbA1c level……………………………………….....11 3.3 A higher baseline HbA1c level, lower BMI, shorter T2D duration, and use of fewer kinds of OADs are predictors to decrease HbA1c levels after 6-month treatment with DPP-4 inhibitors……………..12 Chapter 4 Discussion and Limitations…………………………..……………....16 4.1 Discussion……………………………………………………………..16 4.1.1 Discussion for baseline HbA1c level………………………..16 4.1.2 Discussion for BMI…………………………………………..17 4.1.3 Discussion for T2D duration………………………………...19 4.1.4 Discussion for number of kinds of OADs………………..…19 4.2 Limitations……………………………………………...………….….20 Chapter 5 Conclusion and Perspective………………………………………..…21 REFERENCE…………………………………………………………..………….….22 | |
dc.language.iso | en | |
dc.title | 台灣第二型糖尿病患使用Dipeptidyl Peptidase-4 Inhibitors之效益預測因子分析 | zh_TW |
dc.title | Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus | en |
dc.type | Thesis | |
dc.date.schoolyear | 109-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 王治元(Chih-Yuan Wang),張恬君(Tieng-Chun Chang) | |
dc.subject.keyword | dipeptidyl peptidase-4 inhibitor,第二型糖尿病,糖化血紅素,效益預測因子, | zh_TW |
dc.subject.keyword | dipeptidyl peptidase-4 inhibitor,type 2 diabetes,HbA1c,predictor of efficacy, | en |
dc.relation.page | 27 | |
dc.identifier.doi | 10.6342/NTU202100421 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2021-02-04 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
顯示於系所單位: | 臨床醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-0302202100042100.pdf 目前未授權公開取用 | 3.03 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。